Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Malignant Melanoma: Molecular Mechanism and New Agents for Prevention and...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Malignant Melanoma: Molecular Mechanism and New Agents for Prevention and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 7457

Special Issue Editor

Dr. Carla Rozzo

E-Mail Website
Guest Editor
Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche (CNR), 07100 Sassari, Italy
Interests: cancer molecular biology; melanoma; apoptosis; anticancer therapies; cell cycle; BRAF mutations

Special Issue Information

Dear Colleagues,

Melanoma is a heterogeneous neoplasm arising from dysregulation of a complex set of molecular mechanisms that control melanocytic cell proliferation, by balancing induction (oncogenic) and suppression (tumor suppressive) activity of neoplastic transformation. It is the deadliest form of skin cancer, and it is still one of the most difficult cancers to treat, being markedly refractory to chemotherapy. Recent advances in targeted and immune therapies are showing promising results in clinical trials in terms of overall survival and patient quality of life. However, drug resistance mainly occurs, and novel therapeutic strategies are still needed.

The aim of this Special Issue will be the collection of both basic science and translational research investigation, as well as literature reviews exploring the current knowledge on the complex melanoma molecular signaling network. Great consideration will be given to reports of novel experimental therapies and to studies highlighting new therapies adopted in clinical practices, their evolution, and their effects on improving prognosis. Novel investigations on alternative therapeutic strategies in order to overcome drug resistance will be particularly appreciated, as will findings aiming to improve prevention and early diagnosis of malignant melanoma.

Dr. Carla Rozzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • skin cancer
  • anticancer therapy
  • targeted therapy
  • immunotherapy
  • immune checkpoint inhibitors
  • BRAF inhibitors
  • MEK inhibitors
  • MAPK
  • PI3K/AKT pathway inhibitors
  • drug resistance
  • signaling
  • apoptosis
  • natural products
  • prevention
  • diagnosis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 4332 KiB  
Article
Design and Synthesis of Benzene Homologues Tethered with 1,2,4-Triazole and 1,3,4-Thiadiazole Motifs Revealing Dual MCF-7/HepG2 Cytotoxic Activity with Prominent Selectivity via Histone Demethylase LSD1 Inhibitory Effect
by Mosa Alsehli, Ateyatallah Aljuhani, Saleh K. Ihmaid, Shahenda M. El-Messery, Dina I. A. Othman, Abdel-Aziz A. A. El-Sayed, Hany E. A. Ahmed, Nadjet Rezki and Mohamed R. Aouad
Int. J. Mol. Sci. 2022, 23(15), 8796; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23158796 - 08 Aug 2022
Cited by 10 | Viewed by 2159
Abstract
In this study, an efficient multistep synthesis of novel aromatic tricyclic hybrids incorporating different biological active moieties, such as 1,3,4-thiadiazole and 1,2,4-triazole, was reported. These target scaffolds are characterized by having terminal lipophilic or hydrophilic parts, and their structures are confirmed by different [...] Read more.
In this study, an efficient multistep synthesis of novel aromatic tricyclic hybrids incorporating different biological active moieties, such as 1,3,4-thiadiazole and 1,2,4-triazole, was reported. These target scaffolds are characterized by having terminal lipophilic or hydrophilic parts, and their structures are confirmed by different spectroscopic methods. Further, the cytotoxic activities of the newly synthesized compounds were evaluated using in vitro MTT cytotoxicity screening assay against three different cell lines, including HepG-2, MCF-7, and HCT-116, compared with the reference drug Taxol. The results showed variable performance against cancer cell lines, exhibiting MCF-7 and HepG-2 selectivities by active analogs. Among these derivatives, 1,2,4-triazoles 11 and 13 and 1,3,4-thiadiazole 18 were found to be the most potent compounds against MCF-7 and HepG-2 cancer cells. Moreover, structure–activity relationship (SAR) studies led to the identification of some potent LSD1 inhibitors. The tested compounds showed good LSD1 inhibitory activities, with an IC50 range of 0.04–1.5 μM. Compounds 27, 23, and 22 were found to be the most active analogs with IC50 values of 0.046, 0.065, and 0.074 μM, respectively. In addition, they exhibited prominent selectivity against a MAO target with apparent cancer cell apoptosis, resulting in DNA fragmentation. This research provides some new aromatic-centered 1,2,4-triazole-3-thione and 1,3,4-thiadiazole analogs as highly effective anticancer agents with good LSD1 target selectivity. Full article
(This article belongs to the Special Issue Malignant Melanoma: Molecular Mechanism and New Agents for Prevention and Therapy)
►▼ Show Figures

Figure 1

24 pages, 4905 KiB  
Article
The Anticancer Potential of Doxycycline and Minocycline—A Comparative Study on Amelanotic Melanoma Cell Lines
by Jakub Rok, Zuzanna Rzepka, Justyna Kowalska, Klaudia Banach, Artur Beberok and Dorota Wrześniok
Int. J. Mol. Sci. 2022, 23(2), 831; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23020831 - 13 Jan 2022
Cited by 9 | Viewed by 2170
Abstract
Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that [...] Read more.
Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that minocycline and doxycycline exerted an anti-melanoma effect. The purpose of the study was to assess the anti-melanoma potential and mechanisms of action of minocycline and doxycycline using A375 and C32 human amelanotic melanoma cell lines. The obtained results indicate that the tested drugs inhibited proliferation, decreased cell viability, and induced apoptosis in amelanotic melanoma cells. The treatment caused changes in the cell cycle profile and decreased the intracellular level of reduced thiols and mitochondrial membrane potential. The exposure of A375 and C32 cells to minocycline and doxycycline triggered the release of cytochrome c and activated initiator and effector caspases. The anti-melanoma effect of analyzed drugs appeared to be related to the up-regulation of ERK1/2 and MITF. Moreover, it was noticed that minocycline and doxycycline increased the level of LC3A/B, an autophagy marker, in A375 cells. In summary, the study showed the pleiotropic anti-cancer action of minocycline and doxycycline against amelanotic melanoma cells. Considering all results, it could be concluded that doxycycline was a more potent drug than minocycline. Full article
(This article belongs to the Special Issue Malignant Melanoma: Molecular Mechanism and New Agents for Prevention and Therapy)
►▼ Show Figures

Figure 1

8 pages, 1999 KiB  
Communication
Verteporfin-Loaded Mesoporous Silica Nanoparticles’ Topical Applications Inhibit Mouse Melanoma Lymphangiogenesis and Micrometastasis In Vivo
by Nausicaa Clemente, Ivana Miletto, Enrica Gianotti, Maurizio Sabbatini, Marco Invernizzi, Leonardo Marchese, Umberto Dianzani and Filippo Renò
Int. J. Mol. Sci. 2021, 22(24), 13443; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222413443 - 14 Dec 2021
Cited by 7 | Viewed by 2250
Abstract
Photodynamic therapy (PDT) has been pointed out as a candidate for improving melanoma treatment. Nanotechnology application in PDT has increased its efficacy by reducing side effects. Herein, mesoporous silica nanoparticles (MSNs) conjugated with verteporfin (Ver-MSNs), in use with PDT, were administered in mice [...] Read more.
Photodynamic therapy (PDT) has been pointed out as a candidate for improving melanoma treatment. Nanotechnology application in PDT has increased its efficacy by reducing side effects. Herein, mesoporous silica nanoparticles (MSNs) conjugated with verteporfin (Ver-MSNs), in use with PDT, were administered in mice to evaluate their efficacy on lymphoangiogenesis and micrometastasis in melanoma. Melanoma was induced in mice by the subcutaneous injection of B16-F10 cells. The mice were transcutaneously treated with MSNs, Ver-MSNs, or glycerol and exposed to red light. The treatment was carried out four times until day 20. Lymphangiogenesis and micrometastasis were identified by the immunohistochemical method. Lymphoangiogenesis was halved by MSN treatment compared with the control animals, whereas the Ver-MSN treatment almost abolished it. A similar reduction was also observed in lung micrometastasis. PDT with topically administrated Ver-MSNs reduced melanoma lymphoangiogenesis and lung micrometastasis, as well as tumor mass and angiogenesis, and therefore their use could be an innovative and useful tool in melanoma clinical therapy. Full article
(This article belongs to the Special Issue Malignant Melanoma: Molecular Mechanism and New Agents for Prevention and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop